Life Technologies Expands Line of High-Performance qPCR Instruments

     Life Technologies Expands Line of High-Performance qPCR Instruments

Company simultaneously introduces two flexible systems in the QuantStudio™
product line designed to meet varying throughput and budget needs of customers

PR Newswire

CARLSBAD, Calif., July 24, 2013

CARLSBAD, Calif., July 24, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announces further expansion of its qPCR line of
instruments with the introduction of two platforms: the QuantStudio™ 7 Flex
Real-Time PCR and the QuantStudio™ 6 Flex Real-Time PCR systems. Each provides
varying degrees of flexibility designed to match customers' performance and
budget needs.

"The launch of these systems provides researchers with much needed application
and throughput flexibility with a single instrument," said Chris Linthwaite,
President of Genetic Analysis for Life Technologies. "Combined with our
recently launched QuantStudio™ 3D Digital PCR System and 510(k)-cleared
QuantStudio Dx Real-Time PCR Instrument, this product line now offers flexible
solutions across the continuum of basic research to clinical diagnostics."

The QuantStudio™ 7 Flex Real-Time PCR System provides superior flexibility
with four interchangeable blocks for experiments requiring either 96-well
standard, 96-well fast, 384-well plates or a TaqMan® Array Card (TAC).
Throughput is pushed even further with the system's automation capabilities.
The new instrument is ideal for maximum multiplexing applications with support
for six dyes and 21 filter capabilities.

The QuantStudio™ 6 Flex Real-Time PCR System is the entry-level platform that
is competitively priced to enable customers to buy into the product line's
high performance and flexibility. It is designed for use with three
interchangeable blocks (96-well standard, 96-well fast, or 384-well plates) to
fit mid-level throughput needs. As performance requirements increase with
larger studies, the instrument can also be upgraded to a QuantStudio™ 7 Flex
Real-Time PCR System with the purchase of a kit.

qPCR has long been the workhorse technology used by researchers around the
world to detect and decipher genetic variation underlying biological
processes, agricultural diversity and human disease. Over 25,000 publications
demonstrate the utility and performance of Applied Biosystems® qPCR
instruments in gene expression, genotyping, micro RNA, copy number variation
and protein analysis experiments.

The new platforms mark the fourth and fifth QuantStudio™ systems introduced by
Life Technologies within the last year. Life Technologies first launched the
line of instruments with the QuantStudio 12k Flex Real-Time PCR System in
2012. The QuantStudio™ Dx Real-Time PCR Instrument launched in Europe later
that year and received FDA clearance for use with Quidel's Clostridium
difficile assay in March 2013. Most recently, the company began shipments of
the QuantStudio™ 3D Digital PCR System in June.

"The tremendous pace of these new product introductions demonstrates Life
Technologies commitment to developing truly innovative platforms designed to
support the world's leading scientific work," Linthwaite said. "The
QuantStudio 3D instrument sales have already far surpassed our global
projections, signifying the value researchers attribute to these new

All systems referred to with exception to the QuantStudio™ Dx Real-Time PCR
Instrument are for research use only; not intended for diagnostic purposes.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.